Clinical Trials

168 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT04560322 2026-04-13

Venetoclax-Obinutuzumab +/- Acalabrutinib in R/R CLL

40 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT05388006 2026-03-25

Acalabrutinib, Venetoclax and Durvalumab for the Treatment of Richter Transformation From Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

27 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT05256641 2026-03-10

Acalabrutinib Maintenance for the Treatment of Patients With Large B-cell Lymphoma

Phase 1/2 Recruiting

24 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT05336812 2026-02-19

Acalabrutinib in Combination With Venetoclax or Obinutuzumab for the Treatment of Treatment-naive Chronic Lymphocytic Leukemia

52 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT03516617 2026-02-09

Acalabrutinib With or Without Obinutuzumab in Treating Patients With Early-Stage Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

120 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT04883437 2026-02-09

Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Other Indolent Non-Hodgkin Lymphomas

49 enrolled

Lymphoma, Follicular, Lymphoproliferative Disorders, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT04855695 2026-01-21

Avo In R/R And Previously Untreated MCL

Phase 1/2 Recruiting

72 enrolled

Lymphoma, Lymphoma, Mantle-Cell

NCT07014917 2026-01-06

ESR-23-22182

62 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT06054776 2026-01-05

Acalabrutinib, Obinutuzumab, and Glofitamab for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma

40 enrolled

Lymphoma, Mantle-Cell

NCT04505254 2025-12-26

Acalabrutinib and Obinutuzumab for the Treatment of Chronic Lymphocytic Leukemia

60 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT06757647 2025-12-16

Acalabrutinib for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

61 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT07052695 2025-12-15

Mosunetuzumab for CLL MRD Clearance

Phase 1/2 Recruiting

40 enrolled

Leukemia, Lymphoma, Leukemia, Lymphocytic, Chronic, B-Cell

NCT04484012 2025-11-26

Modified Immune Cells (CD19 CAR T Cells) and Acalabrutinib for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma

36 enrolled

Lymphoma, Mantle-Cell

NCT06958705 2025-11-25

Venetoclax as Consolidation in CLL Patients Treated With BTK Inhibitor Monotherapy

79 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT03128879 2025-11-21

Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL

90 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT04941716 2025-11-19

Acalabrutinib in Combination With Venetoclax for the Treatment of Refractory or Recurrent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, The AVENUE-2 Trial

20 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT05943496 2025-11-06

Tafasitamab, Acalabrutinib, and Obinutuzumab for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

Phase 1 Recruiting

27 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT05197192 2025-08-17

A Phase-3-trial of Acalabrutinib, Obinutuzumab & Venetoclax Compared to Obinutuzumab and Venetoclax in Previously Untreated Patients With High Risk CLL

Phase 3 Recruiting

202 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT06846489 2025-06-03

Acalabrutinib Plus Rituximab for the Treatment of Elderly or Low- to Intermediate-Risk Younger Untreated Mantle Cell Lymphoma

50 enrolled

Lymphoma, Mantle-Cell

NCT05004064 2025-04-09

CARAMEL

48 enrolled

Lymphoma, Mantle-Cell

NCT04566887 2025-02-18

Acalabrutinib With R-CHOP in Previously Untreated Mantle Cell Lymphoma

105 enrolled

Lymphoma, Mantle-Cell

NCT05950997 2024-05-09

A Single Arm Study of Acalabrutinib Conbimed With Obinutuzumab in Chinese Patients With Previously Untreated CLL

Phase NA Recruiting

89 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT04626791 2024-03-12

Modified VR-CAP and Acalabrutinib as First Line Therapy for the Treatment of Transplant-Eligible Patients With Mantle Cell Lymphoma

45 enrolled

Lymphoma, Mantle-Cell

NCT05820841 2023-08-31

ARCHED

Phase 3 Recruiting

330 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT03899337 2023-01-09

STELLAR

105 enrolled